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BUSM researcher finds that blocking 
enzyme activity inhibits HIV infection 
Soon after the discovery of the CD4 receptor on the surface of 
HIV- susceptible cells was announced in 1984, scientists real-
ized that the CD4 protein alone was not sufficient for HIV entry 
into the cell. Now, in a study published in the May 10 issue of 
the Proceedings of the National Academy of Sciences, a group of 
Boston University School of Medicine researchers has found evi-
dence suggesting that an enzyme on the surface of CD4-positive 
cells breaks certain bonds on the virus' outer coat, setting off the 
chain of events that allows the virus to enter the cell. Moreover, 
they found in tissue culture that by blocking the activity of this 
enzyme, they were able to prevent infection of the cell. 
Hugues J.-P. Ryser, MD, a professor of pathology and phar-
macology, and his colleagues have found evidence that the en-
zyme, called protein disulfide-isomerase, or PDl, is present on 
the surface of HlV-susceptible cells and plays a role in breaking 
critical disulfide bonds in the gpl20 glycoprotein on the outer 
coat of the human immunodeficiency virus. This discovery 
could pave the way for new therapeutic strategies against HIV, 
which have been stymied in part because researchers have not 
fully understood how the virus got into the cell. Not only does 
the study shed light on the mechanism by which the HIV vims 
enters the cell, it may also cause scientists to rethink the way 
they look at other vimses. 
Study uncovers new mechanism by which 
nitric oxide regulates blood pressure 
In a study that could open the door to new treatments for arterial 
disease, BUSM investigators have found that nitric oxide acts di-
rectly, as well as indirectly, to relax arteries to control blood 
flow. Until now, scientists believed that the activity of nitric ox-
ide on blood vessel relaxation was purely indirect. The new find-
ings, published in the April 28 Lssue of Nature, could provide a 
new therapeutic direction for diseases such as atherosclerosis, in 
which the indirect action of nitric oxide is impaired. 
Nitric oxide (NO) is a highly reactive gas that for many years 
was known only as a noxious environmental pollutant. In 1987 
scientists discovered that it was also present in the body, and, in 
subsequent years, it became evident that NO was involved in nu-
merous bodily processes, including blood pressure control. 
Scientists now know that when the endothelium—a layer of 
cells lining the blood vessels—sen.ses an increa.se in blood flow, 
it relea.ses nitric oxide. This relea.se of NO then causes the blood 
vessel to relax, by indirectly stimulating an enzyme called guany-
late cyclase to make a chemical messenger known as cyclic 
guanosine monophosphate (cGMP). Cyclic GMP works, in part, 
by inhibiting the entry of calcium, which causes contraction, into 
the cell. At the same time, many scientists also believe, cGMP 
opens potassium channels in the cell membrane, allowing potas-
sium to leave the cell, causing it to relax. Relaxation dilates the 
blood vessel to allow more blood to flow through it. 
In this investigation, Victoria Bolotina, PhD, an assistant re-
search professor of medicine and physiology, and other re-
searchers working in the laboratory of Richard Cohen, MD, a 
professor of medicine and a research professor of physiology, 
have found that NO not only activates the release of cGMP but 
also directly opens potassium channels even when cGMP is not 
present. Their findings could allow researchers to develop new 
treatments aimed at enhancing NO's direct effect on potassium 
channels in diseases such as atherosclerosis, in which cGMP 
pathways do not function. In such diseases, however, some re-
laxation does occur. 
According to Cohen and Bolotina, these results not only shed 
new light on the workings of normal arteries, but they also allow 
researchers to understand how the body compensates when one 
relaxation mechanism has failed. "This investigation shows that 
there are multiple mechanisms by which nitric oxide, the most 
important endogenous vasodilator, works," said Cohen. "The di-
rect activity of nitric oxide on potassium channels may allow the 
body to circumvent the loss of the cGMP pathway in diseased ar-
teries." Future research, he said, will focus on the interaction be-
tween the two known ways in which nitric oxide acts on blood 
vessels, how other vascular disea.ses influence the newly discov-
ered pathway and the development of drugs that enhance the 
pathway. 
Garlic found effective against multi-drug 
resistant strains of bacteria 
A group of BUSM researchers has discovered that an age-old 
folk remedy, garlic, is a surprisingly effective weapon against 
some of the most dangerous antibiotic-resistant bacteria. Staphy-
lococcus aureus and Streptococcus pneumoniae. The re-
searchers, led by Karen Farbman, MD, in the laboratory of 
Jerome Klein, MD, a professor of pediatrics and the director of 
Pediatric Infectious Diseases at Boston City Hospital, found that 
an aqueous extract of fresh garlic cloves was effective against 
more than a dozen common strains of bacteria. The medicinal 
properties of garlic are well-known—it was used to treat infec-
tions long before physicians knew microbes existed—but it.s ef-
fectiveness against antibiotic-resistant bacteria has not been fully 
explored. The findings from this study were published in The Pe-
diatric Infectious Disease Journal. 
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New vitamin D cream reduces 
psoriasis in children 
Investigators at the School of Medicine's General Clinical Re-
search Center have found that an ointment containing the vita-
min D derivative calcitriol safely and effectively reduces 
psoriasis in children, even when the disease does not respond to 
conventional treatments. 
Although psoriasis can be alleviated in many cases by expo-
sure to ultraviolet light or by treatment with corticosteroids, 
these treatments can cause severe side effects, such as thinning 
of the skin, skin cancer, and liver dysfunction in children. With 
calcitriol, however, the researchers—Michael F. Holick, PhD, 
MD, a professor of medicine, dermatology and physiology, and 
Alberto Perez, MD, an assistant professor of medicine—noted 
no side effects in any of the four children they treated. The find-
ings also indicate that calcitriol is safe as a long-term treatment: 
Patients using the ointment for as long as 24 months continued 
to be free of side effects. The findings were presented this 
spring at the annual meeting of the National Institutes of Health 
General Clinical Research Centers. 
Thymopentin has effect in patients 
with cutaneous T-cell lymphoma 
BUSM researchers led by Francine Foss, MD, an assistant pro-
fessor of medicine, have found that thymopentin, a synthetic 
peptide related to the human hormone thymopoietin, is active 
against cutaneous T-cell lymphoma (CTCL), a chronic, progres-
sive lymphoma of the skin, even when other treatments have 
failed. Moreover, unlike other treatments, such as chemother-
apy, thymopentin does not cause side effects. 
In a study presented in April at the American Association for 
Cancer Research meeting, 16 patients with advanced CTCL—15 
of whom had not responded to chemotherapy—were treated in-
travenously with thymopentin three times each week. The re-
searchers noted improvement in eight patients. According to 
Foss, thymopentin acts as an immunomodulator, strengthening 
the immune system by increasing the body's production of natu-
ral killer cells and CDS cells. It has already been shown to de-
crease infection and improve immune function in patients with 
immunologic disorders and to decrea.se viral production in pa-
tients with HIV infection. Thymopentin is part of a fast-growing 
new approach to cancer therapy, in which immunomodulatory 
agents are used to strengthen the body's own defenses at the 
same time that conventional treatments, such as chemotherapy, 
are employed to fight the disease. 
Low levels of essential fatty acids 
linked to high blood lipid levels 
BUSM researchers have found that low levels of essential fatty 
acids (EFAs), also known as polyun.satunited fatty acids, tire a 
major predictor of undesirable blood lipid levels, a well-estab-
lished risk factor for cardiovascular disease. 
Using a new test that measured fatty acid levels in the blood of 
250 men and 250 women participating in the long-running Fram-
ingham Study, Edward N. Siguel, MD, PhD, an adjunct assistant 
research professor of medicine, and Robert H. Lerman, MD, PhD, 
an assistant professor of medicine, found that people with low pro-
portions of polyunsaturated fatty acids relative to monounsatu-
rated and saturated fatty acids were more likely to have a low 
ratio of HDL cholesterol to total cholesterol. Physicians currently 
use the HDL/total cholesterol ratio to characterize the risk for 
heart disease. Current USDA guidelines advise people to eat a 
low-fat diet and to obtain the bulk of their calories from pasta and 
grain, which contain few, if any, EFAs. "When viewed in light of 
our findings, the USDA recommendations are misleading," said 
Siguel. "A low-fat diet is counterproductive if it is low in essen-
tial fatty acids." EFAs are found in fresh vegetables, nuts, and 
seeds, as well as soybean, walnut and canola oils. 
Book by SPH faculty issues new 
guidelines for research on children 
Faculty in the School of Public Health have formulated a set of 
comprehensive guidelines for scientists and others who propose 
to use children as subjects in biomedical, psychosocial and educa-
tional research. The guidelines, together with an exploration of 
the history and law of research on children, are summarized in the 
book Children as Research Subjects: Science, Ethics and Law, 
written by Michael Grodin, MD, a professor of pediatrics and pub-
lic health, and Leonard Glantz, JD, associate director of the 
School of Public Health. 
Before proceeding with re.search on children, the authors said, 
scientists should first determine whether the use of children as re-
search subjects is justified in the individual ca.se; evaluate risks 
from a child-centered point of view; determine whether the re-
search will directly benefit the individual, and, if it will not, 
whether the risk is minimal and the benefits to society great. 
"If the investigators cannot answer these questions, or if they 
have not fully considered these issues, they should not proceed 
with the research," said Grodin. He added that the researchers 
should be particularly vigilant about using dying children as re-
search subjects, because there is often an underlying assumption 
that a dying child cannot be harmed. "But such children are espe-
cially vulnerable," Grodin argues. "How they die is as important 
as when they die." 
Above all, Grodin said, the child's parents should understand 
that research is never conducted for the benefit of the individual, 
but to obtain information that someday might benefit society. 
BUSM, SPH faculty receive grants 
for breast cancer research 
Risa Beth Burns, MD, co-director of the Breast Health Center at 
Boston University Medical Center and an assistant professor of 
medicine at BUSM, has received a grant of $90,000, and Richard 
W. Clapp, ScD, an adjunct assistant professor of public health, 
has received a separate grant of $50,000 from the Brea.st Cancer 
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Initiative program of the Massachusetts Department of Public 
Health. 
Bums' research will determine how often women over the age 
of 65 receive mammography tests for determining breast cancer. 
Clapp will seek to determine whether electromagnetic radiation 
in the workplace is related to breast cancer rates. 
The awards were two of 16 DPH grants awarded for breast 
cancer research. The grants total $1 million. The winners were 
announced by Massachusetts Public Health Commissioner David 
Mulligan and Massachusetts First Lady Susan Weld at an awards 
ceremony held on April 4 in BUMC Hospital's Atrium Lobby. 
Lomber receives Kreig Cortical 
Kudos Cortical Scholar Prize 
Stephen G. Lomber, PhD, a research associate in BUSM's De-
partment of Anatomy and Neurobiology, received the 1994 
Kreig Cortical Kudos Cortical Scholar prize at the Cajal Club's 
meeting on April 24. Lomber was recognized for exemplary doc-
toral research on understanding the structure and function of the 
cerebral cortex. 
The Kreig Cortical Kudos were established by Wendell J. 
Krieg, a distinguished neuroanatomist and pioneer in research on 
the cerebral cortex. Krieg also was a founding member of the Ca-
jal Club, established in 1947, and was its first president. In estab-
lishing these awards it has been his wish that they acknowledge 
excellence in neurological research at several different levels of 
training and experience and that they provide unrestricted re-
sources for the winners. 
BUSM students honored 
Ashok Panigrahy '96 has been awarded the Alpha Omega Al-
pha Student Research Fellowship for the second year in a row. 
As part of the award, Panigrahy received a check for $3,000, 
which will support his research, entitled "Glutamate Receptor 
Development in the Human Brainstem." Last year, he received 
the award for his research titled "Brainstem Nicotinic Acetyl-
choline Receptors in the Sudden Infant Death Syndrome." 
Students in the MD/PhD program of the Department of Pharma-
cology and Experimental Therapeutics have received Medical 
Student Research Fellowships in Pharmacology-Clinical Pharma-
cology. Only six of these fellowships are given each year. 
In this year's competition, Nader Yaghoubi was chosen for 
his proposal, "Electrophysiological investigation of the role of 
phosphorylation in regulation of G A B A A receptors expressed in 
Xenopus oocytes." In 1993, Charles Weaver was selected for 
his studies, "Effect of steroid hormones on NMD A mediated cell 
death in rat hippocampal cells in vitro and in vivo." 
The fellowships, which include $10,000 stipends for one year, 
are provided by the Pharmaceutical Manufacturers Association, 
an international group supported by pharmaceutical companies, 
that is committed to supporting the education and training of sci-
entists, particularly in the area of therapeutics, through support at 
the predoctoral and postdoctoral level. 
Roosevelt Bryant, a second-year student at BUSM, has been se-
lected for the Howard Hughes-National Institutes of Health Re-
search Scholars Program. Bryant's research during the 12-month 
program at the NIH will be in the general area of cell biology and 
regulation, specifically within the cardiovascular system. 
Heidi Abdelhady, a student in the Post-Baccalaureate Program 
at the School of Medicine, who will be entering the first-year 
class at BUSM in September, won first place in the Clinical Re-
search Forum at the Annual Student National Medical Associa-
tion Convention held in Atlanta in March. The title of her 
research project was "The Antimetic Efficacy of Ondansetron vs. 
Ondansetron Plus Dexamethasone." 
Also at the SNMA convention, BUSM's Student National 
Medical Association Chapter won the Chapter of the Year 
Award. 
Briefly noted... 
Barry Zuckerman, MD, chairman of the Department of Pediat-
rics at the School of Medicine and at Boston City Hospital, re-
cently received the Children's Defense Fund Leadership Award. 
Zuckerman was recognized for developing the first clinic in Bos-
ton for teenage mothers and their infants, and for BCH's Women 
and Infants Clinic, which provides drug treatment and child de-
velopment services....Hortensia Amaro, PhD, a professor of 
public health and an assistant professor of pediatrics, received an 
honorary doctoral degree at the May 22nd commencement exer-
cises for Simmons College....The Section of Hypertension, di-
rected by Haralambos Gavras, MD, a professor of medicine, 
recently obtained a three-year NIH grant for "Hypertension and 
Alpha 2 Angiogenic Receptor Expression"....James Menzoian, 
MD, a professor of surgery, has been appointed program commit-
tee chairman for the 23rd Annual Symposium on Vascular Sur-
gery sponsored by the Society for Clinical Vascular Surgery to 
be held in Fort Lauderdale, Fla., in March 1995. In addition, 
Menzoian has been selected as chairman of the program commit-
tee for the 7th Annual Meeting for the American Venous Forum, 
which will be held in February 1995....Stanley Ducharme, PhD, 
a clinical professor of rehabilitation medicine and a hospital-
based rehabilitation psychologist, was recently invited to Wash-
ington to participate in a federally sponsored program on women 
with physical disabilities. The project, sponsored by the National 
Institute of Health and the NationtU Institute on Disability and Re-
habilitation, was designed to develop research agendas within the 
federal government on women's health and disability issues. 
The project focused on the areas of bladder management, sexual-
ity and physical fitness. The results of the conference will be in-
cluded as rehabilitation priorities within the NIH and NIDRR for 
the coming years....Erwin F. Hirsch, MD, FACS, a professor of 
surgery, received the Barry Goldwater Service Award in recogni-
tion of his contributions as a reservist to the specific mission of 
the Department of Surgery at the Uniformed Services University 
of the Health Sciences. Hirsch received the award at the 14th an-
nual USU Surgical Associates Day on April ll....Flaine Alpert, 
MD, an assistant professor of medicine, recently was appointed 
to the Governor's Commission on Domestic Violence.... 
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Carmela R. Abraham, PhD, an associate professor of medi-
cine, has been named one of four recipients nationwide to re-
ceive a Zenith Award from the Alzheimer's Association, Inc. 
The award period is from January 1994 through December 1996 
and totals $199,964, The title of Abraham's grant is "APP-De-
grading Proteases: Proving Their Relevance Using Anti.sense 
Technology." 
Upcoming CME courses 
The following is a list of upcoming courses sponsored by the De-
partment of Continuing Medical Education. 
On June 21, an instructor course on "Advanced Trauma Life 
Support" will be held at Boston University Medical Center. 
"Recent Advances in Medicine" is the title of a seminar that 
will take place from June 23 through June 25 at the Holiday Inn 
Crowne Plaza in Kansas City, Mo. 
From July 25 through July 29 a course titled "Evaluation 
and Treatment of the Injured Athlete: Sports Medicine Up-
date 1994" will be held at the Harbor View Resort on Martha's 
Vineyard. 
For further information, contact the Department of Continuing 
Medical Education at x8-4605 (617/638-4605). 
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